Last reviewed · How we verify
transdermal therapeutic system- nicotine.
At a glance
| Generic name | transdermal therapeutic system- nicotine. |
|---|---|
| Also known as | TDN, Nicorette® invisi 15mg /16hr. |
| Sponsor | Ain Shams University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effectiveness of an Integrated Treatment to Address Smoking Cessation and Anxiety/ Depression in People Living With HIV (NA)
- Depressed Mood Improvement Through Nicotine Dosing 3 (PHASE2)
- Feasibility of Delivering VergeRx at FQHCs (NA)
- Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia (NA)
- Clinical Research Evaluating Smoking Cessation With E-Cigarettes and Nicotine Therapy (NA)
- Preloading With Nicotine Replacement Therapy in HIV-positive Smokers to Improve Self-Efficacy and Quit Attempts (PHASE2, PHASE3)
- Quit or Switch: E-cigarette Study (NA)
- Comparison of Nicotine Replacement Therapy and Electronic Cigarettes for Smoking Cessation in Pakistan (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: